Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.(epub nov 2013)
Auteurs : Awada A, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart-Gebhart M, Schöffski P
Année : 2013
Journal : Invest New Drugs
Volume : 31(3)
Pages : 734-41